The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.
about
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitusHNF1alpha controls renal glucose reabsorption in mouse and man.Functional properties and genomics of glucose transportersTransport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic AgentsDiabetic Kidney Disease: Pathophysiology and Therapeutic TargetsRenal Na(+)-glucose cotransportersProximal nephronSLC2A9 is a high-capacity urate transporter in humansMathematical modeling of renal tubular glucose absorption after glucose loadCloning and characterization of a novel Na+-dependent glucose transporter (NaGLT1) in rat kidneyMolecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidneyHuman genetics as a model for target validation: finding new therapies for diabetes.Obesity: Current and potential pharmacotherapeutics and targets.Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.Sodium-glucose transporter-2 (SGLT2; SLC5A2) enhances cellular uptake of aminoglycosides.The Concise Guide to PHARMACOLOGY 2013/14: transporters.The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.Na+-to-sugar stoichiometry of SGLT3.Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.Developmental changes in renal tubular transport-an overview.Detailed localization of augmented angiotensinogen mRNA and protein in proximal tubule segments of diabetic kidneys in rats and humans.Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusA specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.Emerging treatments in type 2 diabetes: focus on canagliflozin.Comparative cation dependency of sugar transport by crustacean hepatopancreas and intestine.Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetesThe influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.Canagliflozin: a novel treatment option for type 2 diabetes.Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitusFunctional expression of SGLTs in rat brainSGLT2 mediates glucose reabsorption in the early proximal tubule.SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetesSGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuriaGlucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.The pathophysiology of hypertension in patients with obesity.
P2860
Q21195757-C09D668E-36E3-41CB-AA57-810840C85CEFQ24290983-19BAF55B-9B9D-4BE5-9592-77094360F58FQ24651540-38E2D8AB-6C33-47C5-AA9E-CE001CBC68D3Q24685938-B6792EC4-ECDD-4049-B66C-3AF5B059AC93Q28072765-6FAC2CA9-2E8F-46DB-8477-2B9153F9DFBBQ28074843-5D57573E-49D2-4311-AAB7-87473DB69DFDQ28086840-7B0F1E87-AD20-4A03-9D2D-36CEC0FEF1E9Q28141135-A29494FA-7A61-4943-B6A8-AE1A94CF74A6Q28388052-3026CE0F-E856-4F3B-A25B-0B91DC22711FQ28473781-69814064-3599-4EFA-937B-91BDCDB4459EQ28539294-AABD21D9-A2DC-48B9-88DF-2B70F43CA6F1Q28566890-ED0FC87F-6A22-4D8F-9F60-C2A05E1A4BDBQ28580452-D6191C5E-6A48-4592-B19F-4A16A38B7F89Q30234640-D963ED7B-6A02-487A-AD9F-EDA32D0EB83BQ30243992-513019FA-9CA8-46CC-831D-2A21EAB5CFE6Q30248914-718B6BA3-7B97-4D84-870E-EC21AD9A8DD3Q30429061-0CD95309-F289-4F7D-92A5-12956CF15E7EQ30486743-833E188D-E3A0-4297-9407-81D38764A0ACQ30663494-5400FD25-B58C-441B-B7E4-01D0F5352333Q32032221-1E790015-5237-45CB-8E26-C51C1CAABA2FQ33451134-69B0681F-E054-4329-994B-873B5E2558EAQ33639194-B2926129-3196-4E8A-BFB8-662F2E49E401Q33716378-2B094A1A-558B-4840-90A0-55B895065AD8Q33759610-9E8E90EF-F30C-476C-B9FA-965C1E4618D4Q33785128-DE80DE5E-21CE-4260-B53D-12119B31E1E8Q33837017-8DF2DD5D-80AC-408E-8C0E-9788FE749148Q33871321-AFE7860A-5B60-4F65-92D9-C9565B9F67B1Q34084526-24FC4923-CAC0-44B7-8AED-069F4BFB0332Q34109789-7F98F056-BD43-489D-965D-2AE028E006A7Q34131974-DD7F0F95-8185-4E55-9D3F-C1BAF9D6EED2Q34301921-BAA64368-D69A-4F50-AC44-DF165ADB16C0Q34315521-7403205C-2FBC-49B5-A61D-FDE378E3ED28Q34388544-D0A1B09F-D495-4AE9-AB5F-0B3981681353Q34407893-11702023-C72F-412C-8C7F-80AC026227CBQ34426413-06AA94EB-8612-4428-AE40-108338FF6E4DQ34457264-7470E452-C848-4AD3-995F-E22BF4E81578Q34460468-45A9EB35-E07A-4115-AC91-7AC3F39F6D06Q34470786-DDFE9E93-464A-4225-BE38-235C0A2B2C59Q34501684-38A70A23-5A7F-48B6-9ED8-E398F037B52AQ35021492-75F807F3-76EA-4932-9E1A-152971D52815
P2860
The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.
description
1994 nî lūn-bûn
@nan
1994 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
The human kidney low affinity ...... ptive mechanism for D-glucose.
@ast
The human kidney low affinity ...... ptive mechanism for D-glucose.
@en
The human kidney low affinity ...... ptive mechanism for D-glucose.
@nl
type
label
The human kidney low affinity ...... ptive mechanism for D-glucose.
@ast
The human kidney low affinity ...... ptive mechanism for D-glucose.
@en
The human kidney low affinity ...... ptive mechanism for D-glucose.
@nl
prefLabel
The human kidney low affinity ...... ptive mechanism for D-glucose.
@ast
The human kidney low affinity ...... ptive mechanism for D-glucose.
@en
The human kidney low affinity ...... ptive mechanism for D-glucose.
@nl
P2093
P2860
P356
P1476
The human kidney low affinity ...... ptive mechanism for D-glucose.
@en
P2093
P2860
P304
P356
10.1172/JCI116972
P407
P577
1994-01-01T00:00:00Z